Brought to you by 
Incyte and Merus enter Biclonics bispecific antibody collaboration
29 Oct 2021
Executive Summary
Incyte Corp. licensed exclusive rights to up to 11 therapeutic antibodies identified and developed with Merus NV’s Biclonics bispecific antibody discovery platform, including two (undisclosed) preclinical immuno-oncology candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Incyte and Merus enter Biclonics bispecific antibody collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice